Bendamustine salvage therapy for T cell neoplasms (Q33407099)

26 July 2017

title

Bendamustine salvage therapy for T cell neoplasms (English)

1 reference

26 July 2017

1 reference

Luca Baldini

0 references

Stefano Luminari

0 references

Francesco Zaja

1 reference

26 July 2017

Andrés J M Ferreri

1 reference

26 July 2017

Alberto Grossi

1 reference

26 July 2017

Flavia Salvi

1 reference

26 July 2017

Renato Zambello

1 reference

26 July 2017

Maria Goldaniga

1 reference

26 July 2017

Stefano Volpetti

1 reference

26 July 2017

Renato Fanin

1 reference

26 July 2017

publication date

17 April 2013

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

1249-1254

1 reference

Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Stem-cell transplantation in T-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1746-9

10.1007/S00277-013-1746-9

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference